Abbvie Inc.

Abbvie Bahamas Limited

Paul J Brackemeyer

Geoff G Z Zhang

Ahmad Y Sheikh

Rodger F Henry

Thomas B Borchardt

Shuang Chen

Nathaniel Catron

Chih-hung Lee

Jianguo Ji

Michael R Schrimpf

Kevin B Sippy

William H Bunnelle

Tao Li

Lei Shi

Marc J Scanio

Diana L Nersesian

Marlon D Cowart

Lawrence A Black

Youssef L Bennani

Huaqing Liu

James J Napier

Geoff G Zhang

Yuchuan Gong

Seble H Wagaw

Xiaochun Lou

Matthew M Ravn

Deliang Zhou

Agnes E Pal

Moiz Diwan

Zhenping Tian

Geoff GZ Zhang

Willaim H Bunnelle

Marc Scanio

Chih-Hung Lee

Geoff Gz Zhang

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (&#xb0; 2&#x3b8;) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.

Crystaline forms of HCV inhibitor

The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.

Monohydrate of azaadamantane derivatives

Compounds of formula (I) wherein R, R, R, R, R, R, and Rare defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Cyclopropyl amine derivatives

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Azaadamantane derivatives and methods of use

Salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.

Crystalline salts of thieno[3,2-c]pyridine kinase inhibitors with improved cpy safety profile

N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.

Methods of treating cancer with a thieno[3,2-C]pyridine

ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

ABT-263 crystalline forms

ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Salt of ABT-263 and solid-state forms thereof

Crystal forms of kinase inhibitors

Growing community of inventors

Mount Prospect, IL, United States of America

Paul J Brackemeyer